Hemospermia after transrectal ultrasound (TRUS)-guided prostatic biopsy: a prospective study.
Trans-rectal Ultrasound (TRUS) is a safe, cost-effective, radiation free imaging modality for evaluation of prostate. But unfortunately, hemospermia is known to be associated with TRUS -guided prostate biopsy. This study measured the incidence & risk factors, of hemospermia in patients undergoing trans-rectal ultrasonography (TRUS). A prospective observational study involving patients undergoing TRUS for suspected prostate cancer has been conducted at Al-Hussein and Sayed Galal, University Hospitals. 40patients were included in the study. The results showed that 18 out of 40 patients (45%) undergoing TRUS-guided prostatic biopsy, who were able to ejaculate, experienced hemospermia, which was associated with some degree of anxiety. The mean duration of hemospermia was 4 (+/- 1.4) weeks. The number of ejaculations before the complete resolution of hemospermia was 6 (+/- 5.6). None of the clinical and pathological factors were significant predictors of the duration of hemospermia.
Department of Urology, Faculty of Medicine, Al-Azhar University, Nasr City, Egypt.
M A
MA
Abdelkhalek
M
M
Abdelshafy
H A
HA
Elhelaly
M K Seif
MK
El Nasr
D001706:Biopsy / Q000009:adverse effects / Q000379:methods; D051516:Hemospermia / Q000209:etiology* / Q000473:pathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011469:Prostatic Diseases / Q000473:pathology*; D013521:Urologic Surgical Procedures, Male / Q000009:adverse effects